Antibodies News and Research

RSS

BATM provides business and trading update

BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following business and trading update.

26 Jun 2020

GlobalData: Uncertainty during COVID-19 increases demand for immunity-boosting products

Ongoing research around protective immunity against COVID-19 has not yet helped to define ways of how the public can protect themselves from the illness, minimize the symptoms, and avoid re-infection.

26 Jun 2020

IQWiG supports initial assessment of coronavirus diagnostics

As a founding member, the Institute for Quality and Efficiency in Health Care (IQWiG) has been involved in EUnetHTA, a European network for Health Technology Assessment (HTA), since 2006.

26 Jun 2020

Antibody tests may give false hope of immunity, health experts warn

Amid the coronavirus pandemic, health experts warn against the use of antibody tests to determine if a person has immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An antibody test determines if a person developed antibodies against the infection due to past exposure.

26 Jun 2020

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China’s vaccine is the first one to proceed to phase III human trials.

26 Jun 2020

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

Researchers develop unique saliva-based test for COVID-19 detection

University of Saskatchewan researchers are part of two COVID-19-related projects awarded major federal funding today--one to develop a unique saliva-based test for COVID-19 detection and the other to track COVID-19 incidence rates among Canadian dentists.

25 Jun 2020

Study identifies new allergy pathway

Researchers at Johns Hopkins Bloomberg School of Public Health have identified the sequence of molecular events by which tiny, tick-like creatures called house dust mites trigger asthma and allergic rhinitis.

25 Jun 2020

USask researchers receive $900,000 to help strengthen Canada's rapid response to COVID-19

The Canadian Institutes of Health Research has awarded three University of Saskatchewan research teams a total of $900,000 to help strengthen Canada's rapid response to the COVID-19 pandemic which had killed more than 450,000 people worldwide.

25 Jun 2020

Emory launches COVIDVu study to understand the extent of epidemic across the U.S.

Researchers from Emory University's Rollins School of Public Health were awarded a $6.6 million grant from the National Institutes of Health to launch COVIDVu, a national study that will use home tests to develop estimates of the current number of COVID-19 infections and persons with antibody response nationally and across seven heavily impacted states.

25 Jun 2020

New Cochrane review assesses the accuracy of COVID-19 antibody tests

Today Cochrane, a global independent organization that reviews evidence from research to inform health decision-making, publishes a review of studies looking at the accuracy of COVID-19 antibody tests.

25 Jun 2020

Superbug hijacks the wound healing system to cause serious and persistent disease

Monash University researchers have discovered that the devastating bacterial superbug Clostridioides difficile hijacks the human wound healing system in order to cause serious and persistent disease, opening up the development of new therapies to treat the disease.

25 Jun 2020

Novel sensor may be able to test for COVID-19 and influenza simultaneously

The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.

25 Jun 2020

Zika virus during pregnancy can hamper vital collagen development in babies’ brains

Zika virus can hamper vital collagen development in the brains of babies whose mothers were infected with the disease while pregnant, new research reveals, as the search for a vaccine continues.

25 Jun 2020

Early childhood vaccinations may offer protection against COVID-19

A group of Lithuanian and Kurdish scientists have raised a hypothesis that the measles, mumps, and rubella (MMR) vaccine could protect children from COVID-19.

25 Jun 2020

Berkeley Lights announces Opto™ antigen-presenting bead kit to accelerate the expansion of antigen-specific T cells used to develop cell-based therapies

Berkeley Lights, Inc. today announced the Opto Antigen-Presenting Bead kit, a new reagent kit that activates and expands antigen-specific T cells in blood.

From Bruker Cellular Analysis 25 Jun 2020

Study assesses impact of anti-SARS-CoV-2 convalescent plasma in COVID-19 disease

The current COVID-19 pandemic is still very much active in most parts of the world. In the absence of effective antiviral drugs or vaccines, scientists are studying the use of blood plasma from convalescent COVID-19 patients, banking on its neutralizing antibody content.

25 Jun 2020

Immune response variations across the COVID-19 spectrum

A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.

25 Jun 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020